Proud to say I'm in. Modest amount, however, based on their earnings and long term contracts as well as cost consolidation I wouldn't be surprised to see a sturdy nonvolatile >10% bump over the next 12 months.
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
